Agenus Aktie
WKN DE: A1JLKZ / ISIN: US00847G7051
|
10.11.2025 21:32:01
|
Agenus Shares Rise 8.67% On Q3 Results And Clinical Milestones
(RTTNews) - Agenus Inc. (AGEN) rose 8.67% to $4.3250, up $0.3450, after reporting third-quarter 2025 results and announcing key clinical and regulatory advances.
The company disclosed that France has granted reimbursed access for its BOT/BAL therapy in MSS mCRC, and a global Phase 3 trial (BATTMAN) is set to launch in Q4 2025 across 100+ sites.
On the day of the announcement, AGEN experienced unusually heavy trading volume as investors reacted to the news. The stock's 52-week range is $1.14 - $4.50.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Agenus Incmehr Nachrichten
| Keine Nachrichten verfügbar. |